183 related articles for article (PubMed ID: 18205159)
1. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors.
Vagner J; Xu L; Handl HL; Josan JS; Morse DL; Mash EA; Gillies RJ; Hruby VJ
Angew Chem Int Ed Engl; 2008; 47(9):1685-8. PubMed ID: 18205159
[No Abstract] [Full Text] [Related]
2. Enhanced targeting with heterobivalent ligands.
Xu L; Vagner J; Josan J; Lynch RM; Morse DL; Baggett B; Han H; Mash EA; Hruby VJ; Gillies RJ
Mol Cancer Ther; 2009 Aug; 8(8):2356-65. PubMed ID: 19671749
[TBL] [Abstract][Full Text] [Related]
3. Opioid and melanocortin receptors: do they have overlapping pharmacophores?
Lee YS; Agnes RS; Cain JP; Kulkarni V; Cai M; Salibay C; Ciano K; Petrov R; Mayorov A; Vagner J; Trivedi D; Davis P; Ma SW; Lai J; Porreca F; Vardanyan R; Hruby VJ
Biopolymers; 2008; 90(3):433-8. PubMed ID: 17657709
[TBL] [Abstract][Full Text] [Related]
4. Mapping the receptor domains critical for the binding selectivity of delta-opioid receptor ligands.
Meng F; Ueda Y; Hoversten MT; Thompson RC; Taylor L; Watson SJ; Akil H
Eur J Pharmacol; 1996 Sep; 311(2-3):285-92. PubMed ID: 8891611
[TBL] [Abstract][Full Text] [Related]
5. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
6. A 3D model of the delta opioid receptor and ligand-receptor complexes.
Alkorta I; Loew GH
Protein Eng; 1996 Jul; 9(7):573-83. PubMed ID: 8844829
[TBL] [Abstract][Full Text] [Related]
7. Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.
Gharagozlou P; Demirci H; Clark JD; Lameh J
BMC Neurosci; 2002 Nov; 3():19. PubMed ID: 12437765
[TBL] [Abstract][Full Text] [Related]
8. Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors.
di Bosco AM; Grieco P; Diurno MV; Campiglia P; Novellino E; Mazzoni O
Chem Biol Drug Des; 2008 Apr; 71(4):328-35. PubMed ID: 18284554
[TBL] [Abstract][Full Text] [Related]
9. Novel analogues of bifunctional ligands for opioid and melanocortin 4 receptor.
Kulkarni VV; Lee YS; Salibay C; Davis P; Ma SW; Porreca F; Hruby VJ
Adv Exp Med Biol; 2009; 611():195-6. PubMed ID: 19400157
[No Abstract] [Full Text] [Related]
10. A Surprising Recipe for Designing Biased Ligands.
Topiol S
J Med Chem; 2019 Jan; 62(1):141-143. PubMed ID: 29863866
[TBL] [Abstract][Full Text] [Related]
11. Exploring deltorphin II binding to the third extracellular loop of the delta-opioid receptor.
Fadhil I; Schmidt R; Walpole C; Carpenter KA
J Biol Chem; 2004 May; 279(20):21069-77. PubMed ID: 14999000
[TBL] [Abstract][Full Text] [Related]
12. SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors.
Polastron J; Mur M; Mazarguil H; Puget A; Meunier JC; Jauzac P
J Neurochem; 1994 Mar; 62(3):898-906. PubMed ID: 8113811
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity.
Mosberg HI; Fowler CB
J Pept Res; 2002 Dec; 60(6):329-35. PubMed ID: 12464111
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
[TBL] [Abstract][Full Text] [Related]
15. Cell-specific targeting by heterobivalent ligands.
Josan JS; Handl HL; Sankaranarayanan R; Xu L; Lynch RM; Vagner J; Mash EA; Hruby VJ; Gillies RJ
Bioconjug Chem; 2011 Jul; 22(7):1270-8. PubMed ID: 21639139
[TBL] [Abstract][Full Text] [Related]
16. Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.
Kabli N; Martin N; Fan T; Nguyen T; Hasbi A; Balboni G; O'Dowd BF; George SR
Br J Pharmacol; 2010 Nov; 161(5):1122-36. PubMed ID: 20977461
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ligand binding to melanocortin 4 receptors using fluorescent peptides with improved kinetic properties.
Link R; Veiksina S; Rinken A; Kopanchuk S
Eur J Pharmacol; 2017 Mar; 799():58-66. PubMed ID: 28132916
[TBL] [Abstract][Full Text] [Related]
18. A chimeric study of the molecular basis of affinity and selectivity of the kappa and the delta opioid receptors. Potential role of extracellular domains.
Meng F; Hoversten MT; Thompson RC; Taylor L; Watson SJ; Akil H
J Biol Chem; 1995 May; 270(21):12730-6. PubMed ID: 7759527
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a mu-delta opioid receptor complex in CHO cells co-expressing mu and delta opioid peptide receptors.
Rutherford JM; Wang J; Xu H; Dersch CM; Partilla JS; Rice KC; Rothman RB
Peptides; 2008 Aug; 29(8):1424-31. PubMed ID: 18472184
[TBL] [Abstract][Full Text] [Related]
20. Peptide-labeled quantum dots for imaging GPCRs in whole cells and as single molecules.
Zhou M; Nakatani E; Gronenberg LS; Tokimoto T; Wirth MJ; Hruby VJ; Roberts A; Lynch RM; Ghosh I
Bioconjug Chem; 2007; 18(2):323-32. PubMed ID: 17373766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
